Biodesix released data at ASCO-SITC on a new assay that measures PD-L1 in the blood of cancer patients.
Biodesix will present data on blood-based diagnostic testing for PD-L1 at ASCO-SITC 2017; ddPCR test measuring mRNA expression from immune and cancer cells
Biodesix's GeneStrat liquid biopsy test now includes ROS1 and RET mutations. The test helps physicians make treatment decisions for cancer patients.
Clin-TOF successfully integrated into VeriStrat® workflow
Biodesix® and Bioyong Announce Agreement for Joint Development and Commercialization of VeriStrat® Test in Greater China
Biodesix and Bioyong announced a $38M deal for development and commercialization of VeriStrat in China.
Biodesix presents data at the World Lung Conference showing the ability to stratify lung cancer patients treated with immunotherapy
Biodesix won the BizIQ award, 2016 Innovative Company of the Year.
The study results indicate that the tests have the potential to offer clinically relevant information that could help physicians selecting immunotherapies for their patients make the best decision
More Information on Disease State and Trial Options for Patients with Advanced Non-Small Cell Lung Cancer; Evaluating Automated and Manual Workflows in cfDNA Extraction
Biodesix, in partnership with BioRad and Qiagen, presents data from new studies at AMP.
Biodesix Presenting Results From Three Studies at SITC Annual Meeting; Oral Poster Presentation, Two Additional Poster Presentations
Biodesix will present data from three studies at SITC's annual meeting.